<DOC>
	<DOC>NCT03100955</DOC>
	<brief_summary>To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib</brief_summary>
	<brief_title>A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Assess progression free survival, overall survival and toxicity of standard EP regimen combined or not with VEGF tyrosine kinase inhibitor-apatinib. Response measured by RECIST response criteria. Toxicity via physical exam, adverse event review, assessing signs and symptoms, quality of life assessment and blood testing.</detailed_description>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topoisomerase Inhibitors</mesh_term>
	<criteria>1. Histologically or cytologically verified SCLC, extensive stages 2. WHO performance status 0, 1, 2 3. Age 18 years or older 4. Treatment naive 5. Anticipated survival more than 3 months 6. HB &gt;90g/L, ANC&gt;1.5 x 109/L, Platelets &gt;80 x109 /L 7. No prognancy 8. Signed informed consent 1. Limited stage disease 2. Metastastic meningitis, spinal compression, Tumor to main vesicular less than 5mm 3. Uncontrolled hypertension 4. Uncontrolled heart failure 5. Coagulation problem 6. Surgery, trauma, uncontrolled ulcer in 4 weeks. 7. Required by physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>